Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer.

被引：0
|
作者：
McArthur, H. L. [1 ]
Rugo, H. [2 ]
Nulsen, B. [1 ]
Traina, T. [1 ]
Patil, S. [1 ]
Zhou, Q. [1 ]
Steingart, R. [1 ]
Dang, C. [1 ]
Park, J. [2 ]
Moasser, M. [2 ]
Melisko, M. [2 ]
Sugarman, S. [1 ]
Norton, L. [1 ]
Hudis, C. [1 ]
Dickler, M. N. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Univ Calif San Francisco, Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：281S / 282S
页数：2
相关论文
共 50 条
  • [41] The role of preoperative neoadjuvant cytoreductive dose-dense bevacizumab plus docetaxel followed by bevacizumab-doxorubicin-cyclophosphamide regimen in locally advanced operable breast cancer
    Waintraub, S. E.
    Tuchman, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Mature cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA).
    Dang, C.
    Smith, K.
    Fornier, M.
    Sugarman, S.
    Troso, T.
    Lake, D.
    D'Andrea, G.
    Seidman, A.
    Sklarin, N.
    George, R.
    Dickler, M.
    Currie, V
    Gilewski, T.
    Moynahan, M. E.
    Drullinsky, P.
    Poznak, C.
    Robson, M.
    Wasserheit, C.
    Mills, N.
    Steingart, R.
    Norton, L.
    Hudis, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S114 - S115
  • [43] Updated cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA).
    Dang, C.
    Smith, K.
    Fornier, M.
    Sugarman, S.
    Troso-Sandoval, T.
    Lake, D.
    D'Andrea, G.
    Seidman, A.
    Sklarin, N.
    Norton, L.
    Hudis, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 23S - 23S
  • [44] Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Dang, C
    Smith, K
    Lake, D
    Fornier, M
    D'Andrea, G
    Seidman, A
    Sklarin, N
    Troso-Sandoval, T
    Sugarman, S
    Gilewski, T
    Robson, M
    Drullinsky, P
    Moynahan, M
    George, R
    VanPoznak, C
    Panageas, K
    Smith, M
    Norton, L
    Hudis, C
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S98 - S98
  • [45] Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety
    Shimada, Hiroko
    Ueda, Shigeto
    Saeki, Toshiaki
    Shigekawa, Takashi
    Takeuchi, Hideki
    Hirokawa, Eiko
    Sugitani, Ikuko
    Sugiyama, Michiko
    Takahashi, Takao
    Matsuura, Kazuo
    Yamane, Tomohiko
    Kuji, Ichiei
    Hasebe, Takahiro
    Osaki, Akihiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (07) : 642 - 649
  • [46] A phase II neoadjuvant trial of sequential triweekly nanoparticle albumin-bound paclitaxel and cyclophosphamide followed by 5-fluorouracil/epirubicin/cyclophosphamide in the treatment of operable breast cancer.
    Masumoto, Norio
    Kadoya, Takayuki
    Amioka, Ai
    Kajitani, Keiko
    Emi, Akiko
    Shigematsu, Hideo
    Haruta, Rumi
    Kataoka, Tsuyoshi
    Matsuura, Kazuo
    Okada, Morihito
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer (vol 7, 9, 2021)
    Foldi, Julia
    Silber, Andrea
    Reisenbichler, Emily
    Singh, Kamaljeet
    Fischbach, Neal
    Persico, Justin
    Adelson, Kerin
    Katoch, Anamika
    Horowitz, Nina
    Lannin, Donald
    Chagpar, Anees
    Park, Tristen
    Marczyk, Michal
    Frederick, Courtney
    Burrello, Trisha
    Ibrahim, Eiman
    Qing, Tao
    Bai, Yalai
    Blenman, Kim
    Rimm, David L.
    Pusztai, Lajos
    NPJ BREAST CANCER, 2022, 8 (01)
  • [48] Phase 2 study of dose-dense doxorubicin and cyclophosphamide followed by eribulin mesylate with or without prophylactic growth factor for adjuvant treatment of early-stage breast cancer
    Cadoo, K.
    Kaufman, P. A.
    Hudis, C.
    Chang, C.
    Berrak, E.
    Song, J.
    Seidman, A. D.
    Traina, T. A.
    CANCER RESEARCH, 2016, 76
  • [49] Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients
    Sanna, G.
    Pestrin, M.
    Zafarana, E.
    Biagioni, C.
    Cavaciocchi, D.
    Turner, N.
    Di Leo, A.
    Biganzoli, L.
    BREAST, 2013, 22 (05): : 926 - 932
  • [50] Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients
    Coltelli, L.
    Cappelli, S.
    Fontana, A.
    Lucchesi, S.
    Bocci, G.
    Farnesi, A.
    Arrighi, G.
    Finale, C.
    Salvadori, B.
    De Angelis, C.
    Ginocchi, L.
    Falcone, A.
    Fabiani, I.
    Allegrini, G.
    ANNALS OF ONCOLOGY, 2017, 28
12345